It is thus obvious that there is a need for additional non-surgical weight loss therapies that produce clinically significant weight loss and improvements in cardiometabolic risk factors that are comparable to bariatric surgery but without its risks and limitations.
With beloranib, a novel methionine aminopeptidase 2 (MetAP2) inhibitior that reduces the biosynthesis of fat and stimulates its release from fat cells and oxidation, the desired obesity drug may be on the horizon.
"Beloranib is a selective and potent MetAP2 inhibitor that significantly reduces food intake, body weight, fat content, and adipocyte size in obese rodent models (Kim. 2007)." (Kim. 2015).After an investigational 4-week trial in obese women, in whcih intravenous beloranib administration produced weight loss of up to 1 kg per week, as well as improvements in plasma lipids and reductions in hunger (Hughes. 2013), Kim et al. were now the first to conduct a Phase 2 to further investigate the efficacy, safety, and tolerability of a beloranib suspension, administered subcutaneously, for 12 weeks in approximately 150
obese subjects. And their results are stunning.
|Figure 1: Effects of different dosages of beloranib on total body weight and excess body weight (Kim. 2015).|
|Figure 2: Changes in waist circumference, lean mass, body fat, systolic & diastolic blood pressure and hsCRP a reliable marker of whole body inflammation over the course of the 12-week phase 2 trial (Kim. 2015).|
- Foster, Gary D., et al. "What is a reasonable weight loss? Patients' expectations and evaluations of obesity treatment outcomes." Journal of consulting and clinical psychology 65.1 (1997): 79.
- Hughes, T. E., et al. "Ascending dose‐controlled trial of beloranib, a novel obesity treatment for safety, tolerability, and weight loss in obese women." Obesity 21.9 (2013): 1782-1788.
- Kim, Yoo Mee, et al. "Assessment of the anti-obesity effects of the TNP-470 analog, CKD-732." Journal of molecular endocrinology 38.4 (2007): 455-465.
- Kim et al. "Efficacy and Safety of Beloranib for Weight Loss in Obese Adults: A Randomized Controlled Trial." Diabetes, Obesity and Metabolism (2015): Accepted Article.
- Yanovski, Susan Z., and Jack A. Yanovski. "Long-term drug treatment for obesity: a systematic and clinical review." JAMA 311.1 (2014): 74-86.